Skip to content
DataLookout
Start free
Menu

NCT07896109

A Research Study to Check the Safety of NNC9836-0001 When Given to Healthy Participants and Participants With Type 2 Diabetes

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Recruitment opened
    • Start date changed from estimate of Oct 21, 2026 to Oct 22, 2026
    • Site details revised
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Single ascending dose (SAD): Number of Treatment emergent adverse events (TEAEs)
Timeframe: From dosing (day 1) until week 26
Multiple ascending dose (MAD): Number of TEAEs
Timeframe: From dosing (day 1) to week 34

Secondary (4)

SAD: Area under the curve (AUC)0-last, standard deviation (SD): The area under the NNC9836-0001 plasma concentration-time curve from time zero to last measurable concentration after a single dose
SAD:Cmax,SD: The maximum observed NNC9836-0001 plasma concentration after a single dose
MAD: AUC0-28d,MD: The area under the NNC9836-0001 plasma concentration-time curve after multiple doses
MAD: Cmax,MD: The maximum observed NNC9836-0001 plasma concentration after multiple doses

Arms and interventions

NNC9836-0001Experimental

Participants will receive NNC9836-0001 subcutaneously.

PlaceboPlacebo comparator

Participants will receive placebo subcutaneously.

Drugs: NNC9836-0001, Placebo (NaCl)

Sites

1 site in 1 country

  • Profil Institut für Stoffwechselforschung GmbHNeuss, Germany